<DOC>
	<DOC>NCT02539927</DOC>
	<brief_summary>Patients will be treated in accordance with the standard medical practice of the hospital where they have been recruited during their participation in this study. No additional assessments or tests will be required. SAGIT® is a new instrument developed by a group of acromegaly experts to help practicing endocrinologists to manage acromegalic patients and disease activity in their clinical practice and define acromegaly staging. It reports 5 elements: Signs and symptoms - S; Associated comorbidities - A; Growth hormone (GH) concentration - G; Insulin-like growth factor 1(IGF-1) concentration -I; Tumour size- T. The instrument has been pre evaluated during a qualitative pilot study. The purpose of the validation study is to define and validate the scoring of the SAGIT® instrument.</brief_summary>
	<brief_title>Validation Study of the SAGIT® Instrument in Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<criteria>Male or female aged 18 yearsold or above at study inclusion Treatmentnaïve and non treatmentnaïve patients with a diagnosis of acromegaly Data required to complete the SAGIT® tool are available in the patient medical records and do not require additional assessments or tests Data required to complete the SAGIT® tool are recorded within the 3 months preceding the inclusion visit (6 months for MRI) Acute uncontrolled disease requiring intensive care</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>